<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37924444</PMID><DateCompleted><Year>2024</Year><Month>01</Month><Day>09</Day></DateCompleted><DateRevised><Year>2024</Year><Month>01</Month><Day>09</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1435-4373</ISSN><JournalIssue CitedMedium="Internet"><Volume>43</Volume><Issue>1</Issue><PubDate><Year>2024</Year><Month>Jan</Month></PubDate></JournalIssue><Title>European journal of clinical microbiology &amp; infectious diseases : official publication of the European Society of Clinical Microbiology</Title><ISOAbbreviation>Eur J Clin Microbiol Infect Dis</ISOAbbreviation></Journal><ArticleTitle>Sapovirus infection as another cause of persistent viral diarrhea: case series and review of the literature.</ArticleTitle><Pagination><StartPage>55</StartPage><EndPage>59</EndPage><MedlinePgn>55-59</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s10096-023-04695-6</ELocationID><Abstract><AbstractText>Human sapovirus (HuSaV) is a common cause of gastroenteritis worldwide and is responsible for approximately 4% of acute gastroenteritis episodes in Europe. As reported with norovirus, patients with immunocompromised states are at increased risk of developing HuSaV infection, which can lead to persistent diarrhea and chronic viral shedding in some individuals. Chronic infections are incompletely investigated in these patients, and, due to the lack of specific treatment for HuSaV infection, different clinical approaches were carried out in order to provide further evidence on clinical evolution of these patients with different treatments. In this retrospective study, we report five immunocompromised pediatric patients with recurrent diarrhea caused by HuSaV and long-term viral shedding. Stool samples were analyzed by real-time PCR and tested for enteropathogenic viruses and bacteria and protozoa. Among transplant recipients, reduction of immunosuppressant therapy led to clinical improvement and relief of symptoms, maintaining a balance between managing the infection and preventing graft rejection. Nitazoxanide for 14 days was only used in one of these patients, showing to be an effective therapy to achieve reduction in time to resolution of symptoms. Neither nitazoxanide nor modification of immunosuppressant therapy could avoid recurrences. Further investigations are needed to develop new approaches that can both clear the infection and avoid persistent diarrhea in these patients.</AbstractText><CopyrightInformation>© 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Rubio-Mora</LastName><ForeName>Eduardo</ForeName><Initials>E</Initials><Identifier Source="ORCID">0009-0009-2713-9364</Identifier><AffiliationInfo><Affiliation>Servicio de Microbiología y Parasitología, Hospital Universitario La Paz, Paseo de la Castellana, 261, 28046, Madrid, Spain. ermora@salud.madrid.org.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Carrascoso</LastName><ForeName>Guillermo Ruiz</ForeName><Initials>GR</Initials><AffiliationInfo><Affiliation>Servicio de Microbiología y Parasitología, Hospital Universitario La Paz, Paseo de la Castellana, 261, 28046, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rodríguez</LastName><ForeName>Julio García</ForeName><Initials>JG</Initials><AffiliationInfo><Affiliation>Servicio de Microbiología y Parasitología, Hospital Universitario La Paz, Paseo de la Castellana, 261, 28046, Madrid, Spain.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016454">Review</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>11</Month><Day>04</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Eur J Clin Microbiol Infect Dis</MedlineTA><NlmUniqueID>8804297</NlmUniqueID><ISSNLinking>0934-9723</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>SOA12P041N</RegistryNumber><NameOfSubstance UI="C041747">nitazoxanide</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007166">Immunosuppressive Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007223" MajorTopicYN="N">Infant</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D029341" MajorTopicYN="Y">Sapovirus</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017250" MajorTopicYN="Y">Caliciviridae Infections</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005759" MajorTopicYN="Y">Gastroenteritis</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003967" MajorTopicYN="N">Diarrhea</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000258" MajorTopicYN="Y">Adenovirus Infections, Human</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004769" MajorTopicYN="Y">Enterovirus Infections</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007166" MajorTopicYN="N">Immunosuppressive Agents</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005243" MajorTopicYN="N">Feces</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Diarrhea</Keyword><Keyword MajorTopicYN="N">Human sapovirus</Keyword><Keyword MajorTopicYN="N">Immunocompromised</Keyword><Keyword MajorTopicYN="N">Nitazoxanide</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>7</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>10</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>1</Month><Day>9</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>11</Month><Day>4</Day><Hour>21</Hour><Minute>51</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>11</Month><Day>4</Day><Hour>12</Hour><Minute>9</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37924444</ArticleId><ArticleId IdType="doi">10.1007/s10096-023-04695-6</ArticleId><ArticleId IdType="pii">10.1007/s10096-023-04695-6</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Svraka S, Vennema H, van der Veer B et al (2010) Epidemiology and genotype analysis of emerging sapovirus-associated infections across Europe. J Clin Microbiol 48(6):2191–2198. https://doi.org/10.1128/JCM.02427-09</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JCM.02427-09</ArticleId><ArticleId IdType="pubmed">20392905</ArticleId><ArticleId IdType="pmc">2884469</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett S, Gunson RN (2017) The development of a multiplex real-time RT-PCR for the detection of adenovirus, astrovirus, rotavirus and sapovirus from stool samples. J Virolog Methods 242:30–34. https://doi.org/10.1016/j.jviromet.2016.12.016</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jviromet.2016.12.016</ArticleId></ArticleIdList></Reference><Reference><Citation>Wright S, Kleven D, Kapoor R et al (2020) Recurring norovirus &amp; sapovirus infection in a renal transplant patient. IDCases 20:e00776. https://doi.org/10.1016/j.idcr.2020.e00776</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.idcr.2020.e00776</ArticleId><ArticleId IdType="pubmed">32395429</ArticleId><ArticleId IdType="pmc">7210425</ArticleId></ArticleIdList></Reference><Reference><Citation>Neres Silva T, Dábilla N, Santos Corrêa T et al (2020) Sapovirus detection and quantification in fecal samples from allogeneic hematopoietic stem cell transplant recipients. VirusDis 31(3):374–377. https://doi.org/10.1007/s13337-020-00583-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13337-020-00583-1</ArticleId></ArticleIdList></Reference><Reference><Citation>Roos-Weil D, Ambert-Balay K, Lanternier F et al (2011) Impact of norovirus/sapovirus-related diarrhea in renal transplant recipients hospitalized for diarrhea. Transplant 92(1):61–69. https://doi.org/10.1097/TP.0b013e31821c9392</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/TP.0b013e31821c9392</ArticleId></ArticleIdList></Reference><Reference><Citation>Krones E, Högenauer C (2012) Diarrhea in the immunocompromised patient. Gastroenterol Clin North Am 41(3):677–701. https://doi.org/10.1016/j.gtc.2012.06.009</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.gtc.2012.06.009</ArticleId><ArticleId IdType="pubmed">22917171</ArticleId></ArticleIdList></Reference><Reference><Citation>Pietsch C, Liebert UG (2019) Intrahost viral evolution during chronic sapovirus infections. J Clin Virol 113:1–7. https://doi.org/10.1016/j.jcv.2019.02.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcv.2019.02.001</ArticleId><ArticleId IdType="pubmed">30763816</ArticleId></ArticleIdList></Reference><Reference><Citation>Becker-Dreps S, González F, Bucardo F (2020) Sapovirus: an emerging cause of childhood diarrhea. Curr Opin Infect Diseas 33(5):388–397. https://doi.org/10.1097/QCO.0000000000000671</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/QCO.0000000000000671</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghusson N, Vasquez G (2018) Successfully treated norovirus- and sapovirus-associated diarrhea in three renal transplant patients. Case Rep Infect Diseas 2018:1–4. https://doi.org/10.1155/2018/6846873</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2018/6846873</ArticleId></ArticleIdList></Reference><Reference><Citation>Rossignol JF, El-Gohary YM (2006) Nitazoxanide in the treatment of viral gastroenteritis: a randomized double-blind placebo-controlled clinical trial. Aliment Pharmacol Ther 24(10):1423–1430. https://doi.org/10.1111/j.1365-2036.2006.03128.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2036.2006.03128.x</ArticleId><ArticleId IdType="pubmed">17081163</ArticleId></ArticleIdList></Reference><Reference><Citation>Haubrich K, Gantt S, Blydt-Hansen T (2018) Successful treatment of chronic norovirus gastroenteritis with nitazoxanide in a pediatric kidney transplant recipient. Pediatr Transplant 22(4):e13186. https://doi.org/10.1111/petr.13186</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/petr.13186</ArticleId><ArticleId IdType="pubmed">29635723</ArticleId></ArticleIdList></Reference><Reference><Citation>Thiagarajah JR, Martin MG (2022) Approach to chronic diarrhea in neonates and young infants (&lt;6 months). UpToDate Web https://www-uptodate-com.m-hulp.a17.csinet.es/contents/approach-to-chronic-diarrhea-in-neonates-and-young-infants-less-than6 months?search=approach%20to%20chronic%20diarrhea%20in%20neonates&amp;source=search_result&amp;selectedTitle=1~150&amp;usage_type=default&amp;display_rank=1. Accessed 10 June 2023.</Citation></Reference><Reference><Citation>Lozano NA, Lozano A, Marini V et al (2018) Expression of FcRn receptor in placental tissue and its relationship with IgG levels in term and preterm newborns. Am J Reprod Immunol 80(3):e12972. https://doi.org/10.1111/aji.12972</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/aji.12972</ArticleId><ArticleId IdType="pmc">6153031</ArticleId></ArticleIdList></Reference><Reference><Citation>Boniel S, Szymańska K, Śmigiel R et al (2021) Kabuki syndrome—clinical review with molecular aspects. Genes 12(4):468. https://doi.org/10.3390/genes12040468</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/genes12040468</ArticleId><ArticleId IdType="pubmed">33805950</ArticleId><ArticleId IdType="pmc">8064399</ArticleId></ArticleIdList></Reference><Reference><Citation>Lindsley AW, Saal HM, Burrow TA et al (2016) Defects of B-cell terminal differentiation in patients with type-1 Kabuki syndrome. J Aller Clin Immunol 137(1):179–187.e10. https://doi.org/10.1016/j.jaci.2015.06.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaci.2015.06.002</ArticleId></ArticleIdList></Reference><Reference><Citation>Adam MP, Hudgins L, Hannibal M (2022) Kabuki syndrome GeneReviews Web. https://www.ncbi.nlm.nih.gov/books/NBK62111/. Accessed 12 May 2023.</Citation></Reference><Reference><Citation>Boillat Blanco N, Kuonen R, Bellini C et al (2011) Chronic norovirus gastroenteritis in a double hematopoietic stem cell and lung transplant recipient. Transpl Infect Dis 13(2):213–215. https://doi.org/10.1111/j.1399-3062.2010.00565.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1399-3062.2010.00565.x</ArticleId></ArticleIdList></Reference><Reference><Citation>Engelen MA, Gunia S, Stypmann J (2011) Elimination of norovirus in a chronic carrier under immunosuppression after heart transplantation--effect of everolimus. Transpl Int 24(11):e102–e103. https://doi.org/10.1111/j.1432-2277.2011.01330.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1432-2277.2011.01330.x</ArticleId><ArticleId IdType="pubmed">21880072</ArticleId></ArticleIdList></Reference><Reference><Citation>Rossignol JF (2014) Nitazoxanide: a first-in-class broad-spectrum antiviral agent. Antiviral Res 110:94–103. https://doi.org/10.1016/j.antiviral.2014.07.014</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.antiviral.2014.07.014</ArticleId><ArticleId IdType="pubmed">25108173</ArticleId><ArticleId IdType="pmc">7113776</ArticleId></ArticleIdList></Reference><Reference><Citation>Hedvat J, Salerno DM, Kovac D et al (2022) Nitazoxanide treatment for norovirus infection in solid organ transplant recipients. Clin Transplant 36(3):e14594. https://doi.org/10.1111/ctr.14594</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ctr.14594</ArticleId><ArticleId IdType="pubmed">35032413</ArticleId></ArticleIdList></Reference><Reference><Citation>Kempf B, Edgar JD, Mc Caughey C et al (2017) Nitazoxanide is an ineffective treatment of chronic norovirus in patients with X-linked agammaglobulinemia and may yield false-negative polymerase chain reaction findings in stool specimens. J Infect Dis 215(3):486–487. https://doi.org/10.1093/infdis/jiw497</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiw497</ArticleId><ArticleId IdType="pubmed">28362905</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis A, Cortez V, Grodzki M et al (2020) Infectious norovirus is chronically shed by immunocompromised pediatric hosts. Viruses 12(6)):619. https://doi.org/10.3390/v12060619</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v12060619</ArticleId><ArticleId IdType="pubmed">32516960</ArticleId><ArticleId IdType="pmc">7354526</ArticleId></ArticleIdList></Reference><Reference><Citation>Daniel-Wayman S, Fahle G, Palmore T et al (2018) Norovirus, astrovirus, and sapovirus among immunocompromised patients at a tertiary care research hospital. Diagn Microbiol Infect Dis 92:143–146. https://doi.org/10.1016/j.diagmicrobio.2018.05.017</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.diagmicrobio.2018.05.017</ArticleId><ArticleId IdType="pubmed">29934072</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>